SCHEMBL25749356

SCHEMBL25749356

CCc1ccc(COC(=O)N(C)CCN(C)C(=O)C(C)(C)C)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRSS1 P07477 1/20 0.41
▸ TPSAB1 Q15661 1/20 0.41
▸ F13A1 P00488 1/20 0.37
▸ TGM2 P21980 1/20 0.37
▸ TGM1 P22735 1/20 0.37
▸ ALDH1A1 P00352 5/20 0.37
▸ HPGD P15428 4/20 0.37
▸ SMN1; SMN2 Q16637 3/20 0.37
▸ KDM4E B2RXH2 2/20 0.37
▸ NPC1 O15118 2/20 0.37
▸ GAA P10253 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ RXRA P19793 1/20 0.36
▸ RXRB P28702 1/20 0.36
▸ MAPT P10636 3/20 0.36
▸ NAAA Q02083 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ MEN1 O00255 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25748676 0.87 ESRRG (0.48) PRSS1TPSAB1ALDH1A1SMN1; SMN2NPC1
SCHEMBL25567568 0.87 PRSS1 (0.43) PRSS1TPSAB1F13A1TGM2TGM1
SCHEMBL21132846 0.87 F13A1 (0.41) PRSS1TPSAB1F13A1TGM2TGM1
SCHEMBL26192260 0.86 PPARA (0.41) PRSS1TPSAB1F13A1TGM2TGM1
SCHEMBL25751042 0.85 MEN1 (0.45) PRSS1TPSAB1F13A1TGM2TGM1
SCHEMBL19592679 0.85 F13A1 (0.44) PRSS1TPSAB1F13A1TGM2TGM1
SCHEMBL25964314 0.82 PRSS1 (0.46) PRSS1TPSAB1F13A1TGM2TGM1
SCHEMBL25964144 0.82 PRSS1 (0.43) PRSS1TPSAB1F13A1TGM2TGM1
SCHEMBL13596297 0.82 F13A1 (0.40) PRSS1TPSAB1F13A1TGM2TGM1
SCHEMBL25881500 0.81 L3MBTL1 (0.51) PRSS1TPSAB1TGM2ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11685742-B2 Anti-tumor compound and preparation method and use thereof DUALITY BIOLOGICS (SUZHOU) CO., LTD. (CN) 2023-06-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11685742-B2 Anti-tumor compound and preparation method and use thereof RCC2, REN, VHL PRSS1 1874/4885TPSAB1 532/4885F13A1 3824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback